8-K - BridgeBio Pharma, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

BridgeBio Pharma submitted an NDA to the FDA for BBP-418 to treat LGMD2I/R9, with potential approval and U.S. launch anticipated in late 2026/early 2027, which could be the first therapy for this condition.

Key Takeaways

1BridgeBio submitted an NDA to the FDA for oral BBP-418 for the treatment of LGMD2I/R9.

2The submission includes interim Phase 3 FORTIFY data demonstrating statistically significant and clinically meaningful improvements in ambulation and pulmonary function with a favorable safety profile.

3Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027.

4If approved, BBP-418 would be the first and only approved therapy for LGMD2I/R9 and potentially the first approved therapy for any form of LGMD.

5BBP-418 has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the EMA.

6The Company intends to initiate clinical studies of BBP-418 in LGMD2I/R9 for individuals less than 12 years of age and in LGMD2M/2U in the near future.

Current Report Details

Event Type

Other Event

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

. | Other Events | |---|---| On March 30, 2026, BridgeBio Pharma, Inc. issued a press release titled “BridgeBio Submits NDA to FDA for BBP-418 for Individuals L

Other Event

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. | Exhibit | Description | |---|---| | | | | 99.1 | Press Release titled “BridgeBio Submits NDA to

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EXHIBIT 99.1